Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes

Hypertension Research

Volumn 30, Issue 1, 2007, Pages 23-30

  Eguchi, Kazuo ^a,b   Tomizawa, Hidenori ^b   Ishikawa, Joji ^b   Hoshide, Satoshi ^b   Numao, Toshio ^c   Fukuda, Toshio ^c   Shimada, Kazuyuki ^b   Kario, Kazuomi ^b  

^a NewYork Presbyterian Hospital   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c Shioya General Hospital   (Japan)

Author keywords

Aldosterone; Insulin resistance; Metformin; Pioglitazone; Von Willebrand factor

Indexed keywords

ADIPONECTIN; ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NEUROHORMONE; PIOGLITAZONE; VON WILLEBRAND FACTOR;

ADULT; AGED; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; EARLY INTERVENTION; FACE EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MULTICENTER STUDY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

ADIPONECTIN; AGED; ALDOSTERONE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS; FASTING; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; VON WILLEBRAND FACTOR;

EID: 33847041377     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.23     Document Type: Article

References (44)

1. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924.
2. The Decode Study Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-696.
3. Haffner S, Temprosa M, Crandall J, et al: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572.
4. Muntner P, He J, Chen J, Fonseca V, Whelton PK: Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14: 686-695.
5. Kannel W, Wilson P, Zhang T: The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991; 121: 1268-1273.
6. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003; 290: 486-494.
7. Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program - Adult Treatment Panel III to Japanese Men - the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203-208.
8. Langenfeld M, Forst T, Hohberg C, et al: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531.
9. Dormandy JA, Charbonnel B, Eckland DJA, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
10. Orchard TJ, Temprosa M, Goldberg R, et al: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Ann Intern Med 2005; 142: 611-619.
11. Caballero AE, Delgado A, Aguilar-Salinas CA, et al: The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004; 89: 3943-3948.
12. World Health Organization (WHO): Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Reports of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, WHO, 1999.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
14. Matsui Y, Kario K, Ishikawa J, Eguchi K, Hoshide S, Shimada K: Reproducibility of arterial stiffness indices (pulse wave velocity and augmentation index) simultaneously assessed by automated pulse wave analysis and their associated risk factors in essential hypertensive patients. Hypertens Res 2004; 27: 851-857.
15. Holm S: A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65-70.
16. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
17. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
18. Pfutzner A, Marx N, Lubben G, et al: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
19. Satoh N, Ogawa Y, Usui T, et al: Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499.
20. Gaillard V, Casellas D, Seguin-Devaux C, et al: Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 2005; 46: 372-379.
21. Chu NV, Kong APS, Kim DD, et al: Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25: 542-549.
22. Lind L: Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203-214.
23. Durbin RJ: Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-285.
24. Fujiwara T, Saitoh S, Takagi S, et al: Development and progression of atherosclerotic disease in relation to insulin resistance and hyperinsulinemia. Hypertens Res 2005; 28: 665-670.
25. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
26. Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K: Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 2003; 26: 705-710.
27. Ogawa Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Uchiyama M: Usefulness of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Hypertens Res 2005; 28: 51-57.
28. Furuhashi M, Ura N, Higashiura K, et al: Low adiponectin level in young normotensive men with a family history of essential hypertension. Hypertens Res 2005; 28: 141-146.
29. van Wijk JPH, de Koning EJP, Cabezas MC, et al: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005; 143: 337-346.
30. Derosa G, Cicero A, Dangelo A, et al: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917-924.
31. Chen K, Chen J, Li D, Zhang X, Mehta JL: Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-γ ligand pioglitazone. Hypertension 2004; 44: 655-661.
32. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner H-R, Burnier M: Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004; 89: 1140-1145.
33. Semenkovich CF: TZDs and diabetes: testing the waters. Nat Med 2005; 11: 822-824.
34. Mudaliar S, Chang A, Henry R: Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003; 9: 406-416.
35. Haenni A, Reneland R, Lind L, Lithell H: Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension. J Hypertens 2001; 19: 107-112.
36. Leurs PB, Stolk RP, Hamulyak K, van Oerle R, Grobbee DE, Wolffenbuttel BHR: Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002; 25: 1340-1345.
37. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL: Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485.
38. Hadigan C, Meigs JB, Rabe J, et al: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86: 939-943.
39. Grant P: The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19: 64-456.
40. Nakamura T, Matsuda T, Kawagoe Y, et al: Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382-1386.
41. Ishibashi M, Egashira K, Hiasa K, et al: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
42. Wakino S, Hayashi K, Tatematsu S, et al: Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255-262.
43. Nakanishi N, Shiraishi T, Wada M: Brachial-ankle pulse wave velocity and metabolic syndrome in a Japanese population: the Minoh study. Hypertens Res 2005; 28: 125-131.
44. Seo H, Kang T, Park S, et al: Insulin resistance is associated with arterial stiffness in nondiabetic hypertensives independent of metabolic status. Hypertens Res 2005; 28: 945-951.